{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:06:37Z","timestamp":1784541997642,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR304262"],"award-info":[{"award-number":["NIHR304262"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.coi.2026.102746","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:36:37Z","timestamp":1772210197000},"page":"102746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Composite and pragmatic measures in psoriatic arthritis: bridging trials and clinical feasibility"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-2001","authenticated-orcid":false,"given":"Ji-Hyoun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102746_bib1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchilin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102746_bib2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladmann","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_sbref4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3899\/jrheum.2024-0515","article-title":"Composite outcome measures for psoriatic arthritis: OMERACT and 3 and 4 visual analog scale progress in 2023","volume":"51","author":"Leung","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170150","article-title":"Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT Working Group","volume":"44","author":"Ogdie","year":"2017","journal-title":"J Rheumatol"},{"issue":"Supplement 3","key":"10.1016\/j.coi.2026.102746_sbref6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3899\/jrheum.2025-0268","article-title":"Composite outcome measures for psoriatic arthritis: project updates 2024","volume":"52","author":"Ribeiro","year":"2025","journal-title":"J Rheum"},{"key":"10.1016\/j.coi.2026.102746_sbref7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40744-024-00690-1","article-title":"Filling the \u201cGAP\u201d in real-world assessment of psoriatic arthritis disease activity: performance characteristics of a global\/pain composite endpoint","volume":"11","author":"Tillett","year":"2024","journal-title":"Rheuma Ther"},{"key":"10.1016\/j.coi.2026.102746_sbref8","series-title":"Composite Outcome Measures that Successfully Differentiate Active Treatments from Placebo in Psoriatic Arthritis Trials: A GRAPPA-OMERACT Systematic Review and Network Meta-analysis","author":"Annfeldt","year":"2025"},{"key":"10.1016\/j.coi.2026.102746_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003548","article-title":"Validity and score interpretation of the 12-item psoriatic arthritis impact of disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis","volume":"10","author":"Gossec","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102746_sbref10","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1093\/rheumatology\/keaf002","article-title":"Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study","volume":"64","author":"L\u00f3pez-Medina","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102746_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-025-05819-1","article-title":"Discordance between patient and physician global assessments of psoriatic arthritis activity: an observational study in 13 Arab countries","volume":"45","author":"Abbas","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.coi.2026.102746_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10235659","article-title":"Implementation of the treat-to-target concept in psoriatic arthritis: a real-world study","volume":"10","author":"Gazitt","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102746_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/annrheumdis-2016-211010","article-title":"Modification of the psoriatic arthritis disease activity score (PASDAS)","volume":"77","author":"Helliwell","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_bib15","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1093\/rheumatology\/keac025","article-title":"Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis","volume":"61","author":"Mulder","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102746_bib16","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/rheumatology\/kez254","article-title":"Implementing Psoriatic Arthritis Disease Activity Score-guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?","volume":"58","author":"Mulder","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102746_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3899\/jrheum.2023-1085","article-title":"Defining the minimal important change and meaningful hange value of the disease activity index for psoriatic arthritis: a Chinese longitudinal study","volume":"51","author":"Liu","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004062","article-title":"Window of opportunity in psoriatic arthritis: the earlier the better?","volume":"10","author":"Snoeck Henkemans","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102746_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001002","article-title":"Measurement properties of the minimal disease activity criteria for psoriatic arthritis","volume":"5","author":"Coates","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102746_bib22","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s40744-023-00588-4","article-title":"Identification of the minimal disease activity domains achieved based on different treatments in psoriatic arthritis","volume":"10","author":"Scriffignano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coi.2026.102746_sbref23","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3899\/jrheum.2024-0152","article-title":"The development and validation of a novel training infographic for the physician global visual analog scale in psoriatic arthritis","volume":"51","author":"Gunawardana","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib24","article-title":"Implementation of the treat-to-target approach in psoriatic arthritis and its outcomes in routine clinical practice","volume":"15","author":"Din","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2026.102746_bib25","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/1756-185X.14829","article-title":"Optimal composite measures for psoriatic arthritis","volume":"26","author":"Huang","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/acr2.11714","article-title":"Association between achievement of clinical disease control and patient-reported outcomes in patients with psoriatic arthritis","volume":"6","author":"Kavanaugh","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3899\/jrheum.160386","article-title":"Defining low disease activity states in psoriatic arthritis using novel composite disease instruments","volume":"43","author":"Lubrano","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1811-4","article-title":"Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis","volume":"21","author":"Wervers","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2026.102746_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0030-y","article-title":"Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients\u2019 health-related quality of life and productivity","volume":"2","author":"Coates","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002706","article-title":"Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis","volume":"8","author":"Snoeck Henkemans","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102746_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02838-2","article-title":"Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning","volume":"24","author":"Queiro","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2026.102746_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.7172","article-title":"Minimal disease activity in psoriatic arthritis predicts low impact of disease","volume":"78","author":"Kasavkar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102746_bib33","article-title":"Validation and clinical interpretability of PsAID-12 in patients with PsA: association with MDA status","volume":"60","author":"da Cruz Ribeiro e Souza","year":"2020","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-022-00443-y","article-title":"Residual disease associated with suboptimal treatment in psoriatic arthritis: a real-world PsAID-12 analysis","volume":"9","author":"Coates","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coi.2026.102746_bib35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40744-021-00343-7","article-title":"The \u201cclimb\u201d towards minimal disease activity in psoriatic rthritis","volume":"8","author":"Lubrano","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coi.2026.102746_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02474-2","article-title":"Relationships between psoriatic arthritis composite measures and patient-reported outcomes: a post hoc analysis of OPAL Broaden and OPAL Beyond","volume":"23","author":"Coates","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2026.102746_bib37","article-title":"Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies","volume":"58","author":"Schneeberger","year":"2023","journal-title":"Semin Arthrits Rheum"},{"key":"10.1016\/j.coi.2026.102746_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152237","article-title":"Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs\/tsDMARDs and potential barriers","volume":"62","author":"Ortolan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102746_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40744-018-0135-1","article-title":"Patient perspective on the burden of akin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey","volume":"6","author":"Merola","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coi.2026.102746_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.160924","article-title":"The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical etting","volume":"44","author":"Di Carlo","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib41","first-page":"603","article-title":"Psychometric properties of patient global assessment in psoriatic arthritis: a systematic literature review","volume":"51","author":"Chessa","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_sbref42","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002972","article-title":"Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis","volume":"9","author":"Kasiem","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102746_bib43","article-title":"Clinical and psychological factors associated with discordance between patient and physician global assessments in psoriatic arthritis","author":"Cinakli","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.coi.2026.102746_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10184106","article-title":"Real-world data from a multi-center Study: insights to psoriatic arthritis care","volume":"10","author":"Batko","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102746_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152546","article-title":"Barriers and facilitators to application of treat-to-target management in psoriatic arthritis and axial spondyloarthritis in practice: a systematic literature review","volume":"69","author":"Webers","year":"2024","journal-title":"Semin Arthritis Rheum"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:36:08Z","timestamp":1784540168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"alternative-id":["S0952791526000233"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102746","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composite and pragmatic measures in psoriatic arthritis: bridging trials and clinical feasibility","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102746"}}